NCT07878988
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07878988
Title This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors LTZ Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.